TG Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.About TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.
CEOMichael Sean Weiss
CEOMichael Sean Weiss
Employees338
Employees338
HeadquartersMorrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded1993
Founded1993
Employees338
Employees338
TGTX Key Statistics
Market cap5.02B
Market cap5.02B
Price-Earnings ratio11.39
Price-Earnings ratio11.39
Dividend yield—
Dividend yield—
Average volume3.26M
Average volume3.26M
High today$31.65
High today$31.65
Low today$31.62
Low today$31.62
Open price$31.55
Open price$31.55
Volume385.00
Volume385.00
52 Week high$46.48
52 Week high$46.48
52 Week low$25.28
52 Week low$25.28
Stock Snapshot
With a market cap of 5.02B, TG Therapeutics(TGTX) trades at $31.65. The stock has a price-to-earnings ratio of 11.39.
On 2026-01-23, TG Therapeutics(TGTX) stock moved within a range of $31.62 to $31.65. With shares now at $31.65, the stock is trading +0.1% above its intraday low and 0.0% below the session's peak.
Trading volume for TG Therapeutics(TGTX) stock has reached 385, versus its average volume of 3.26M.
The stock's 52-week range extends from a low of $25.28 to a high of $46.48.
The stock's 52-week range extends from a low of $25.28 to a high of $46.48.
TGTX News
Nasdaq 7d
Interesting TGTX Put And Call Options For March 20thInvestors in TG Therapeutics Inc (Symbol: TGTX) saw new options become available this week, for the March 20th expiration. At Stock Options Channel , our YieldB...
Analyst ratings
78%
of 9 ratingsBuy
77.8%
Hold
11.1%
Sell
11.1%
People also own
Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.